Learn more

GERON CORP

Overview
  • Total Patents
    846
  • GoodIP Patent Rank
    8,867
  • Filing trend
    ⇧ 27.0%
About

GERON CORP has a total of 846 patent applications. It increased the IP activity by 27.0%. Its first patent ever was published in 1993. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are SILENCE THERAPEUTICS GMBH, ALNYLAM PHARMACEUTICALS and PROSENSA TECH B V.

Patent filings per year

Chart showing GERON CORPs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Andrews William H 94
#2 Pongracz Krisztina 91
#3 Morin Gregg B 90
#4 Harley Calvin B 82
#5 Gryaznov Sergei 67
#6 Gold Joseph D 59
#7 Carpenter Melissa K 54
#8 Cech Thomas R 49
#9 Chapman Karen B 48
#10 Nakamura Toru 46

Latest patents

Publication Filing date Title
JP2020176145A Combination treatment for hematological cancers
WO2020112854A1 Methods of treating myelodysplastic syndrome
AU2019315406A1 Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor
CA3069010A1 Methods of treating myelodysplastic syndrome
TW201706284A Methods of polynucleotide preparation using multivalent cation salt compositions
CA2925500A1 Phosphorodiamidate backbone linkage for oligonucleotides
JOP20200257A1 Oligonucleotide Compositions and Methods of Making the Same
US2015344963A1 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
BR112015012507A2 in vitro method of selecting an individual diagnosed or suspected of having cancer and using a telomerase inhibitor
US2015342982A1 Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
CN111617252A Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative tumors
CA2887702A1 C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
US2014163090A1 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US2014121261A1 C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
US2014155465A1 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
CA2857490A1 Guanine analogs as telomerase substrates and telomere length affectors
CA2829804A1 Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells
AU2012236880A1 Telomere length measurement in formalin-fixed, paraffin embedded (FFPE) samples by quantitative PCR
WO2011106671A1 Assay for telomerase activity
WO2010151782A1 Differentiated pluripotent stem cell progeny depleted of extraneous phenotypes